IBRX

ImmunityBio Inc.

Price

$8.22

return (12m)

232.79%

p/e

-8.72

p/bv

-8.28

DIVIDEND YIELD

0.00%

IBRX price

ImmunityBio

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment IBRX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-2.72%

3 months

20.70%

1 year

232.79%

2 years

54.51%

5 years

3.27%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals IBRX

Valuation

P/E

-8.72

Sector -3.10

Industry -3.10

P/BV

-8.28

Sector 1.78

Industry 1.78

P/Revenue (PSR)

52.22

Sector 2.00

Industry 2.00

EV/EBITDA

-44.75

Sector -202.91

Industry -202.91

EV/EBIT

-43.76

Sector -40.75

Industry -40.75

P/EBITDA

-10.05

Sector -19.52

Industry -19.52

P/EBIT

-9.86

Sector -64.80

Industry -64.80

P/Total Assets

13.78

Sector 1.06

Industry 1.06

P/Net Current Assets

-7.01

Sector -9.29

Industry -9.29

P/Working Capital

23.90

Sector -121.95

Industry -121.95

EPS

-0.95

Sector -1.78

Industry -1.78

BVPS

-1.00

Sector 2.01

Industry 2.01

Efficiency

Gross Margin

99.34%

Sector 41.24%

Industry 41.24%

EBITDA Margin

-380.05%

Sector -21,194.51%

Industry -21,194.51%

EBIT Margin

-100.00%

Sector -35.37%

Industry -35.37%

Net Profit Margins

-100.00%

Sector -35.81%

Industry -35.81%

Asset Turnover

0.08

Sector 0.03

Industry 0.03

Profitability

ROE

94.89%

Sector -57.47%

Industry -57.47%

ROA

-157.89%

Sector -59.48%

Industry -59.48%

ROIC

-116.28%

Sector -1,878.27%

Industry -1,878.27%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

5.72

Sector 2.92

Industry 2.92

Net Debt / EBITDA

-0.30

Sector -19.80

Industry -19.80

Net Debt / EBIT

-0.29

Sector -4.14

Industry -4.14

Net Debt / Equity

-0.06

Sector -33,113.00

Industry -33,113.00

Gross Debt / Equity

-0.40

Sector -0.84

Industry -0.84

Equity/Assets

-1.66

Sector 0.46

Industry 0.46

Liabilities/Assets

2.66

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

181.74%

Sector -

Industry -

5Y Earnings CAGR

23.40%

Sector -

Industry -

Fundamentals IBRX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
IBRX ImmunityBio Inc.	$8.22	232.79%	0.00%	-8.72	-8.28	94.89%	-100.00%
PFE Pfizer Inc.	$30.03	31.74%	5.80%	38.97	1.98	5.07%	6.80%
ABBV AbbVie Inc.	$285.64	29.28%	2.40%	79.90	-85.04	-106.44%	9.81%
NVO Novo Nordisk A/S	$39.05	-22.59%	4.76%	9.52	5.05	53.11%	35.32%
MRK Merck & Co. Inc.	$145.27	70.91%	2.34%	113.15	8.55	7.56%	4.77%
AZN AstraZeneca PLC	$171.49	4.72%	1.89%	20.48	5.28	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$61.48	48.44%	4.11%	13.44	5.59	41.59%	18.87%
ZTS Zoetis Inc.	$81.03	-43.41%	2.58%	12.83	10.75	83.77%	27.69%
AMGN Amgen Inc.	$439.26	54.71%	2.25%	27.32	20.44	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$805.02	39.84%	0.46%	19.24	2.63	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$125.63	89.92%	0.00%	35.61	102.60	288.13%	24.86%
MCK McKesson Corporation	$1,000.77	25.44%	0.34%	26.09	-31.01	-118.84%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$523.93	24.33%	0.00%	30.31	6.59	21.76%	35.00%
CAH Cardinal Health Inc.	$249.57	55.62%	0.81%	34.72	-21.85	-62.92%	0.67%
ARGX argenx SE	$873.71	6.90%	0.00%	13.05	3.49	26.71%	25.47%
HRMY Harmony Biosciences Holdings Inc.	$36.13	19.44%	0.00%	11.35	2.06	18.14%	18.88%
BIIB Biogen Inc.	$250.69	67.25%	0.00%	44.37	1.96	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

IBRX - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT ImmunityBio

ImmunityBio Inc.

Average Investor10 user rating

4.0 (11 people)

United States

12 years

Founded: 2014

2015

Time since IPO - 11 years

684

Employees

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, specializing in therapies designed to activate and enhance the immune system’s ability to identify and destroy disease cells.

Its research strategy centers on combining different immune-modulating technologies to generate durable immune responses in complex diseases, particularly in oncology.

Core areas of development include:

Cancer immunotherapies targeting solid tumors
Therapeutic vaccine platforms based on viral vectors
Allogeneic cell therapies designed to activate immune responses
NK cell and T-cell activation technologies
Immunotherapy candidates for oncology and infectious diseases

ImmunityBio’s clinical programs primarily focus on conditions such as bladder cancer, metastatic tumors, and other solid cancers, with multiple therapies undergoing different stages of clinical development.

Industry dynamics affecting the company include regulatory approval processes, clinical trial outcomes, competition in oncology immunotherapy, research and development funding, and broader healthcare policy developments.

ImmunityBio, Inc. is listed on the Nasdaq under the ticker IBRX.

History and Development

ImmunityBio was founded in 2014 in California as a biotechnology company focused on developing immunotherapy platforms for cancer treatment.

Early research programs centered on designing therapies capable of stimulating stronger immune responses against cancer cells through combinations of vaccine-based technologies and immune cell activation strategies.

A key milestone occurred in 2021, when NantKwest merged with ImmunityBio, consolidating the companies’ immunotherapy research platforms and expanding the combined organization’s clinical development pipeline.

Since then, the company has continued advancing clinical programs in oncology and infectious disease treatments, while investing in research infrastructure and manufacturing capabilities designed to support the development of next-generation immunotherapies.

Additional Information

ImmunityBio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $8.66 billion, with shareholders equity totaling $-1.05 billion.

The company employs approximately 684 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, ImmunityBio Inc. reported $165.79 million in revenue, generating net income of $-992.36 million.

Key financial metrics include a P/E ratio of -8.72, a price-to-book (P/B) ratio of -8.28, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker IBRX.

Market cap

$8.66 billion

Net worth

$-1.05 billion

$-1,045,761,000.00

Assets

$628.50 million

$628,504,000.00

Total Shares Outstanding

1.05 billion

1,050,070,000

Average Daily Trading Volume

$12.22 million

$12,222,886.34

Sector

Health Care

Industry

Biotechnology

IBRX

IBRX revenue and profits

Financial Results IBRX

DRAG THE FRAME TO SEE MORE DATA

IBRX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,000.77 25,44% (12M)

P/E

26.09

0.34%

ROE

-118.84%

P/BV

-31.01

CAH - Cardinal Health

$249.57 55,62% (12M)

P/E

34.72

0.81%

ROE

-62.92%

P/BV

-21.85

ABBV - AbbVie

$285.64 29,28% (12M)

P/E

79.90

2.40%

ROE

-106.44%

P/BV

-85.04

MRK - Merck & Co.

$145.27 70,91% (12M)

P/E

113.15

2.34%

ROE

7.56%

P/BV

8.55

AZN - AstraZeneca

$171.49 3,76% (12M)

P/E

20.48

1.89%

ROE

25.77%

P/BV

5.28

PFE - Pfizer

$30.03 31,74% (12M)

P/E

38.97

5.80%

ROE

5.07%

P/BV

1.98

BMY - Bristol-Myers Squibb

$61.48 48,44% (12M)

P/E

13.44

4.11%

ROE

41.59%

P/BV

5.59

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,000.77 25,44% (12 M)

P/L

26.09

0.34%

ROE

-118.84%

P/VP

-31.01

CAH - Cardinal Health

$249.57 55,62% (12 M)

P/L

34.72

0.81%

ROE

-62.92%

P/VP

-21.85

ABBV - AbbVie

$285.64 29,28% (12 M)

P/L

79.90

2.40%

ROE

-106.44%

P/VP

-85.04

MRK - Merck & Co.

$145.27 70,91% (12 M)

P/L

113.15

2.34%

ROE

7.56%

P/VP

8.55

AZN - AstraZeneca

$171.49 3,76% (12 M)

P/L

20.48

1.89%

ROE

25.77%

P/VP

5.28

PFE - Pfizer

$30.03 31,74% (12 M)

P/L

38.97

5.80%

ROE

5.07%

P/VP

1.98

BMY - Bristol-Myers Squibb

$61.48 48,44% (12 M)

P/L

13.44

4.11%

ROE

41.59%

P/VP

5.59

Frequently Asked Questions

What is the price of ImmunityBio (IBRX) today?

The current price of ImmunityBio (IBRX) is $8.22. The stock began the year trading around $1.98 and is currently priced at $8.22. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does ImmunityBio (IBRX) pay dividends?

ImmunityBio (IBRX) did not pay dividends over the past year.

Is ImmunityBio (IBRX) a good investment?

ImmunityBio (IBRX) is currently trading at $8.22 with a P/E ratio of -8.72. This represents a -593% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 232.79%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy ImmunityBio (IBRX) stock?

You can buy ImmunityBio (IBRX) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol IBRX and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of ImmunityBio (IBRX) yield today?

Over the past month, ImmunityBio (IBRX) has returned -2.72% — 232.79% over the past year, and 3.27% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of ImmunityBio (IBRX) today at the current price of $8.22 your total investment would be $822.00.

Based on historical performance, the investment would have grown to approximately:

$2,735.53 after 1 year
$848.88 after 5 years
$822.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

IBRX

ImmunityBio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IBRX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING IBRX WITH OTHER STOCKS

ABOUT ImmunityBio

ImmunityBio Inc.

United States

12 years

2015

684

History and Development

Additional Information

PROFIT X PRICE IBRX

Financial Results IBRX

IBRX cash flow

Asset, Revenue and Profit Growth - IBRX

IBRX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions